Search results
Nektar (NKTR) Up on Positive New Data From Eczema Study
Zacks via Yahoo Finance· 8 months agoNektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated...
Nektar (NKTR) Starts New Restructuring Plan to Curb Cash Burn
Zacks via Yahoo Finance· 1 year agoThe new restructuring plan will allow Nektar (NKTR) to extend its cash runway into mid-2026. The...
Nektar's (NKTR) Q2 Earnings and Revenues Miss Estimates
Zacks via Yahoo Finance· 2 years agoNektar (NKTR) reports dismal second-quarter 2022 results. The company's operating expenses increased...
"We've got a problem with the other band who registered the name and are trying to stop us from...
Louder Sound via Yahoo News· 4 months agoNektar. When vocalist Roye Albrighton died in 2016, Nektar’s future looked uncertain, yet in 2019 a...
Nektar Aruba review
MusicRadar via Yahoo News· 10 months agoNektar Aruba Beat Composer Nektar Aruba: What is it? Nektar’s 16-pad drum controller, Aruba, pairs perfectly with the versatile Nektarine plugin and...
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
Zacks via Yahoo Finance· 2 months agoNektar Therapeutics NKTR reported an adjusted loss of 22 cents per share for the fourth quarter of...
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
Zacks via Yahoo Finance· 1 year agoNektar Therapeutics NKTR reported a loss (excluding non-cash goodwill and other impairment charges)...
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
Zacks via Yahoo Finance· 9 months agoNektar Therapeutics NKTR reported a loss of 27 cents per share for the second quarter of 2023, which...
Is Nektar Therapeutics (NASDAQ:NKTR) In A Good Position To Deliver On Growth Plans?
Simply Wall St. via Yahoo Finance· 3 months agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of...
Simply Wall St. via Yahoo Finance· 10 months agoKey Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is...
